TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36111808

Group type: EXPERIMENTAL
Intervention: Total Gut Restoration (TGR) system supplementation (five probiotic Bacillus strains, prebiotic mixture, immunoglobulin concentrate, amino acids and prebiotic flavonoids) for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupplemented controls
Number of subjects: 0
Study: 32023365

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 35366574

Group type: EXPERIMENTAL
Intervention: 4 mg AZ-009
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33470648

Group type: COMPARATOR
Intervention: P-VIG (prolonged bout expending 300 kcal at 70% VO2R)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: P-MOD (prolonged bout expending 300 kcal at 50% VO2R)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: S-MOD (short bout expending 150 kcal at 50% VO2R)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CTL (nonexercise control session)
Number of subjects: 24
Study: 36261468

Group type: EXPERIMENTAL
Intervention: CCRT combined with aerobic exercise (CAE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 34325888

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33027758

Group type: EXPERIMENTAL
Intervention: Dance group (n = 78)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (n = 56)
Number of subjects: 134
Study: 35130086

Group type: EXPERIMENTAL
Intervention: Epidural Morphine (5 mg) and Bupivacaine (0.25%, 2 mL)
Number of subjects: 100
Study: 34539142

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention with mutual cooperation system (Group C)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Pharmacist intervention without mutual cooperation system (Group B)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Pharmacist intervention without HFSR (Group A)
Number of subjects: 134
Study: 32050099

Group type: EXPERIMENTAL
Intervention: Eccentric cycle training (ECC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional cycle training (CON)
Number of subjects: 24
Study: 35438014

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 33975325

Group type: EXPERIMENTAL
Intervention: High protein (HP) diet (1.5 g protein/kg body weight)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal protein (NP) diet (0.8 g protein/kg body weight)
Number of subjects: 54
Study: 35382702

Group type: EXPERIMENTAL
Intervention: Socially branded messages discouraging EC use (themes: general wellness, pride, health harms)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Socially branded messages discouraging EC use (pride-themed messages)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Socially branded messages discouraging EC use (general wellness and health harms themes)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Socially branded messages discouraging EC use
Number of subjects: 457
Study: 34593030

Group type: EXPERIMENTAL
Intervention: Modified-Paleo diet with calorie counting
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Modified-Paleo diet with fixed diet plan
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Medium-carbohydrate diet with calorie counting
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Medium-carbohydrate diet with fixed diet plan
Number of subjects: 80
Study: 35382844

Group type: EXPERIMENTAL
Intervention: Dual long-acting bNAbs infusions (3BNC117-LS and 10-1074-LS) followed by Analytical Treatment Interruption (ATI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo infusions followed by ATI
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Open-label LS bNAbs after viral rebound in Stage 2
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dual long-acting bNAbs infusions
Number of subjects: 72
Study: 33717406

Group type: EXPERIMENTAL
Intervention: Vigabatrin therapy
Number of subjects: 0
Study: 32097203

Group type: EXPERIMENTAL
Intervention: One suction device (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Two suction devices (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (post-wash)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (post-filtration)
Number of subjects: 30
Study: 35196986

Group type: EXPERIMENTAL
Intervention: MynxGrip vascular closure device (VCD)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Manual compression (MC)
Number of subjects: 869
Study: 35737383

Group type: EXPERIMENTAL
Intervention: FOLFOX (mFOLFOX6) with trastuzumab and nivolumab (1 mg/kg × 4/240 mg for up to 12 months)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg × 4 for up to 12 weeks) with trastuzumab and nivolumab
Number of subjects: 88

Group type: COMPARATOR
Intervention: FOLFOX (mFOLFOX6)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 88
Study: 32354380

Group type: EXPERIMENTAL
Intervention: Triglyceride-rich lipoprotein cholesterol (TRL-C)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Small-dense low-density lipoprotein cholesterol (sdLDL-C)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Both TRL-C and sdLDL-C
Number of subjects: 976
Study: 35110300

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) administered via two 40 minute intravenous infusions at baseline and 24 hours.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (saline) administered via two 40 minute intravenous infusions at baseline and 24 hours.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) at week 6.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (saline) at week 6.
Number of subjects: 156
Study: 33656394

Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritionally balanced drink (Control)
Number of subjects: 0
Study: 34338876

Group type: EXPERIMENTAL
Intervention: Novel electrosurgical temperature-controlled instrument
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cold-steel with localized bipolar cauterization (control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control side (cold-steel)
Number of subjects: 48
Study: 33438360

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 248

Group type: COMPARATOR
Intervention: No intervention (Control group: non-DM patients)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: DM patients
Number of subjects: 248
Study: 33516297

Group type: EXPERIMENTAL
Intervention: FnCas12a
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LbCas12a
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: AsCas12a
Number of subjects: 3
Study: 35129299

Group type: EXPERIMENTAL
Intervention: Group-based community health club effective use counselling
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Individualized effective use counselling
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Community-based PrEP dispensary
Number of subjects: 603

Group type: COMPARATOR
Intervention: Standard-of-care PrEP delivery with individualized effective use counselling
Number of subjects: 603

Group type: COMPARATOR
Intervention: Standard-of-care PrEP delivery with group-based community health effective use counselling
Number of subjects: 603
Study: 34615624

Group type: EXPERIMENTAL
Intervention: Building blocks activity (LEGO robot creation)
Number of subjects: 0
Study: 35125305

Group type: EXPERIMENTAL
Intervention: SVF-enriched autologous lipotransfer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-enriched autologous lipotransfer
Number of subjects: 15
Study: 32507479

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH; 32.0 °C-34.0 °C)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Fever control (35.5 °C-37.0 °C)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Hb levels during early phase
Number of subjects: 130
Study: 35533363

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 187
Study: 34462986

Group type: EXPERIMENTAL
Intervention: Deep Learning model based on T2WI
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Deep Learning model based on DWI
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Deep Learning model based on T2WI + DWI (combination)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Radiomics model based on T2WI
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Radiomics model based on DWI
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Radiomics model based on T2WI + DWI (combination)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Assessment by Radiologist 1
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Assessment by Radiologist 2
Number of subjects: 217
Study: 33595427

Group type: EXPERIMENTAL
Intervention: 5% lidocaine cream applied perianally for 10 minutes (group 1)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally for 10 minutes (group 2)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally for 20 minutes (group 3)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 10 minutes (group 4)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 20 minutes (group 5)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 1% lidocaine nerve block plus 5% lidocaine cream applied perianally and internally for 10 minutes (group 6)
Number of subjects: 252

Group type: COMPARATOR
Intervention: PPNB only (control group 7)
Number of subjects: 252
Study: 32216142

Group type: EXPERIMENTAL
Intervention: Concerns about family disruptions during deployment
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Harassment during deployment
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Postdeployment social support
Number of subjects: 223
Study: 34952292

Group type: EXPERIMENTAL
Intervention: adrabetadex
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NPC-SS (Niemann-Pick Disease, type C1 Severity Scale)
Number of subjects: 56
Study: 34782430

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine targeting tumor blood vessel antigens with immediate dasatinib (Arm B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dendritic cell vaccine targeting tumor blood vessel antigens with delayed dasatinib (Arm A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine targeting tumor blood vessel antigens
Number of subjects: 16
Study: 35347874

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for MDD
Number of subjects: 8
Study: 33655423

Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks (q2w)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks (q4w)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg q2w and Dupilumab 300 mg q4w
Number of subjects: 251
Study: 32445688

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) plus standardised medical care
Number of subjects: 368

Group type: COMPARATOR
Intervention: Standardised medical care alone
Number of subjects: 368
Study: 36204396

Group type: EXPERIMENTAL
Intervention: Fruits last meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fruits first meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Postprandial exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fruits last meal vs Fruits first meal
Number of subjects: 36
Study: 35254390

Group type: EXPERIMENTAL
Intervention: Intensive SBP target <120 mm Hg
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard SBP target <140 mm Hg
Number of subjects: 547

Group type: COMPARATOR
Intervention: Intensive vs Standard Treatment
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Intensive Treatment in participants with history of cardiovascular disease
Number of subjects: 547
Study: 36131389

Group type: EXPERIMENTAL
Intervention: VTC modality of NEUROPSI Breve
Number of subjects: 32

Group type: COMPARATOR
Intervention: Face-to-face modality of NEUROPSI Breve
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adapted version of NEUROPSI Breve
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Original version of NEUROPSI Breve
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Online (VTC) modality
Number of subjects: 32
Study: 33162176

Group type: EXPERIMENTAL
Intervention: Facebook campaign
Number of subjects: 17271

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17271

Group type: EXPERIMENTAL
Intervention: Facebook campaign in lowest SES quartile
Number of subjects: 17271

Group type: COMPARATOR
Intervention: Control group in lowest SES quartile
Number of subjects: 17271

Group type: EXPERIMENTAL
Intervention: Facebook campaign in second SES quartile
Number of subjects: 17271

Group type: COMPARATOR
Intervention: Control group in second SES quartile
Number of subjects: 17271
Study: 32179446

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS) followed by 8x paclitaxel and carboplatin (TC regimen)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NACT) with 4x TC, interval debulking surgery (IDS), 4x TC
Number of subjects: 301

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS)
Number of subjects: 301
Study: 35877734

Group type: EXPERIMENTAL
Intervention: Spirulysat®
Number of subjects: 40
Study: 33661306

Group type: EXPERIMENTAL
Intervention: PVE/HVE
Number of subjects: 199

Group type: COMPARATOR
Intervention: PVE
Number of subjects: 199
Study: 35875898

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Osteopathic medicine (OM)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 121
Study: 34002561

Group type: EXPERIMENTAL
Intervention: Fire needling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Filiform needling
Number of subjects: 60
Study: 32378422

Group type: EXPERIMENTAL
Intervention: 5 mg oral melatonin supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 36403564

Group type: EXPERIMENTAL
Intervention: DLR ss‐EPI
Number of subjects: 87

Group type: COMPARATOR
Intervention: ss‐EPI
Number of subjects: 87
Study: 33864989

Group type: EXPERIMENTAL
Intervention: MISSION‐CJ (wraparound treatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High engagement in MISSION‐CJ
Number of subjects: 100
Study: 32981534

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone (LAI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral risperidone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive remediation and LAI antipsychotic medication
Number of subjects: 60
Study: 33879469

Group type: EXPERIMENTAL
Intervention: Deep learning approach using fundus photographs
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Deep learning approach using fundus autofluorescence (FAF) images
Number of subjects: 1302
Study: 32907565

Group type: EXPERIMENTAL
Intervention: Awareness of HIV positive status
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: On ART
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Viral suppression
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Awareness of HIV positive status by sex
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: On ART by sex
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Viral suppression by sex
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Awareness of HIV positive status by age group
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: On ART by age group
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Viral suppression by age group
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 90-90-90 indicators by area type
Number of subjects: 1000
Study: 35019901

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (LV-HIT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-volume high-intensity interval training (HV-HIT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 34284802

Group type: EXPERIMENTAL
Intervention: Usual care plus behaviour change therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 32536026

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (RG)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MG)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 77
Study: 35585981

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP) with oxygenated banked red blood cell (RBC) based solution for 1h at 36°C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMP
Number of subjects: 0
Study: 33630675

Group type: EXPERIMENTAL
Intervention: Exercise (60 minutes at 60% VO2peak)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hot water immersion (40.5oC for 60 minutes)
Number of subjects: 12
Study: 34821492

Group type: EXPERIMENTAL
Intervention: nomask (nm)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: surgical mask (cm)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FFP2/N95 mask (ffpm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: surgical mask (cm) and FFP2/N95 mask (ffpm)
Number of subjects: 16
Study: 32005280

Group type: EXPERIMENTAL
Intervention: Oncokompas eHealth self-management application
Number of subjects: 136

Group type: COMPARATOR
Intervention: Waiting-list control group (no access to Oncokompas for 3 months)
Number of subjects: 136
Study: 36976583

Group type: EXPERIMENTAL
Intervention: Prolonged grief disorder (PGD) diagnosis
Number of subjects: 328

Group type: COMPARATOR
Intervention: No prolonged grief disorder (PGD) diagnosis
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cause of death (COVID-19)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cause of death (brain hemorrhage)
Number of subjects: 328
Study: 34016091

Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention including teacher-led classroom teaching, parental engagement sessions, environmental modifications, and improved handwashing stations.
Number of subjects: 3081

Group type: COMPARATOR
Intervention: Control group with routine health education.
Number of subjects: 3081

Group type: EXPERIMENTAL
Intervention: Combined prevalence of Ascaris lumbricoides and Trichuris trichiura infections at end-line survey.
Number of subjects: 3081

Group type: EXPERIMENTAL
Intervention: Prevalence of Ascaris lumbricoides.
Number of subjects: 3081

Group type: EXPERIMENTAL
Intervention: Prevalence of Trichuris trichiura.
Number of subjects: 3081

Group type: EXPERIMENTAL
Intervention: STH infection intensity.
Number of subjects: 3081
Study: 32081875

Group type: EXPERIMENTAL
Intervention: MR‐TRYX framework
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment for pleiotropic pathways
Number of subjects: 0
Study: 35230884

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (40 mg/m2)
Number of subjects: 261

Group type: COMPARATOR
Intervention: 3-weekly cisplatin (100 mg/m2)
Number of subjects: 261
Study: 33401957

Group type: EXPERIMENTAL
Intervention: 12-week aerobic and resistance training program (high-intensity interval training and resistance exercises 3 days/week)
Number of subjects: 0
Study: 33110130

Group type: EXPERIMENTAL
Intervention: 0.3% atropine eye drops
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.3% atropine eye drops with myopic defocus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.3% atropine eye drops with hyperopic defocus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atropine treatment after 3 and 6 months
Number of subjects: 20
Study: 35138402

Group type: EXPERIMENTAL
Intervention: Niclosamide 2 g by mouth daily for 7 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Niclosamide
Number of subjects: 73
Study: 33625509

Group type: EXPERIMENTAL
Intervention: Constituent plus engagement messages
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Constituent-only messages
Number of subjects: 789

Group type: COMPARATOR
Intervention: Control condition (messages about littering cigarette butts)
Number of subjects: 789
Study: 35392902

Group type: EXPERIMENTAL
Intervention: Social reward feature (meal for donation upon quiz completion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No social reward feature (control group)
Number of subjects: 30
Study: 34108297

Group type: EXPERIMENTAL
Intervention: Cement thickness of 50 µm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cement thickness of 100 µm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cement thickness of 200 µm
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cement thickness (general)
Number of subjects: 45
Study: 34506986

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (15 mg every 6 hours)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 246
Study: 33792832

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg sustained release tablet, orally three times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, orally three times daily
Number of subjects: 60
Study: 33231914

Group type: EXPERIMENTAL
Intervention: 2 weeks of knee immobilization
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ambulatory recovery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hindlimb suspension for 7 days (HS 7d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Weight bearing (WB) control
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reloading after HS
Number of subjects: 28